Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical <i>SMN1</i> and <i>SMN2</i> Gene-Specific Sequencing to Enhance the Clinical Sensitivity of Spinal Muscular Atrophy Diagnostic Testing.

Human mutation·2025
Same author

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.

Leukemia·2022
Same author

Characterization of Prion Disease Associated with a Two-Octapeptide Repeat Insertion.

Viruses·2021
Same author

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Leukemia·2021
Same author

Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.

JCO precision oncology·2021
Same author

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Leukemia·2021

Related Experiment Video

Updated: Jun 8, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Spinal muscular atrophy: a time for screening.

Thomas W Prior1

  • 1Department of Pathology, The Ohio State University, Columbus, Ohio 43210, USA. thomas.prior@osumc.edu

Current Opinion in Pediatrics
|September 11, 2010
PubMed
Summary

Newborn screening for spinal muscular atrophy (SMA) enables early intervention before irreversible motor neuron loss. Carrier screening is crucial for preventing new cases of SMA, an autosomal recessive neuromuscular disorder.

More Related Videos

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles
09:07

Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles

Published on: September 25, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)

Published on: March 17, 2012

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles
09:07

Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles

Published on: September 25, 2015

Area of Science:

  • Genetics
  • Neuromuscular Disorders
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is a severe autosomal recessive neuromuscular disorder.
  • Mutations in the survival motor neuron (SMN1) gene cause SMA, affecting ~1 in 10,000 live births.
  • Current SMA therapies are limited, making early detection and prevention critical.

Purpose of the Study:

  • To review the molecular genetics of SMA.
  • To emphasize the importance of newborn screening for early intervention.
  • To highlight population carrier screening for SMA prevention.

Main Methods:

  • Review of current literature on SMA genetics and therapeutic trials.
  • Analysis of the role of the SMN2 gene in SMA phenotype.
  • Discussion of newborn screening and carrier detection strategies.

Main Results:

  • The SMN2 gene copy number correlates with SMA phenotype severity.
  • SMN2 modulation and gene therapy show promise in preclinical models.
  • Newborn screening allows for early intervention before significant motor neuron loss.

Conclusions:

  • Newborn screening facilitates timely intervention for SMA patients.
  • Population carrier screening is essential for preventing new SMA cases.
  • Treatment and prevention strategies are complementary for managing SMA.